Literature DB >> 35584696

Stereopure oligo therapy for ALS.

John J Rossi1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35584696      PMCID： PMC9171261          DOI： 10.1016/j.ymthe.2022.04.026

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   12.910


× No keyword cloud information.
  4 in total

Review 1.  Progress in antisense technology.

Authors:  Stanley T Crooke
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

2.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

3.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

4.  Preclinical evaluation of WVE-004, aninvestigational stereopure oligonucleotide forthe treatment of C9orf72-associated ALS or FTD.

Authors:  Yuanjing Liu; Amy Andreucci; Naoki Iwamoto; Yuan Yin; Hailin Yang; Fangjun Liu; Alexey Bulychev; Xiao Shelley Hu; Xuena Lin; Sarah Lamore; Saurabh Patil; Susovan Mohapatra; Erin Purcell-Estabrook; Kristin Taborn; Elena Dale; Chandra Vargeese
Journal:  Mol Ther Nucleic Acids       Date:  2022-04-20       Impact factor: 10.183
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.